Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer

• DOI: 10.1016/j.xcrm.2024.101499
• Publication Date: 2024-04-05T18:03:00Z
• Authors: Haiming Chen; Yi Ma; Juqing Xu; Wenxiang Wang; Hao Lu; Cheng Quan; Fan Yang; Yiming Lu; Hao Wu; Mantang Qiu
• Keywords: Clinical Significance; Diagnostic biomarker

Lung cancer mortality is exacerbated by late-stage diagnosis. Emerging evidence indicates the potential clinical significance of distinct microbial signatures as diagnostic and prognostic biomarkers across various cancers. However, circulating microbiome DNA (cmDNA) profiles are underexplored in lung (LC). Here, whole-genome sequencing performed on plasma LC patients healthy controls (HCs). Differentially enriched species identified between HC. A model developed, which has a high sensitivity 87.7% achieves an AUC 93.2% independent validation dataset. Crucially, this demonstrates capability to detect early-stage LC, achieving 86.5% for stage I 87.1% tumors <1 cm. In addition, we construct cmDNA recurrence, precisely predicts recurrence after surgery. Overall, study highlights significant alterations indicating its early diagnosis recurrence.